OTCBB ALERTS

[Mandroid]

GBIW _ NEWS Genesis Bioventures Announces Breast Cancer Marker Receives Diagnostic and Therapeutic Patent Approval
PR Newswire - February 02, 2006 09:30

NEW YORK, Feb 02, 2006 /PRNewswire-FirstCall via COMTEX/ -- Genesis Bioventures, Inc. (OTCBB:GBIW) announced today that Mammastatin, the breast cancer marker exclusively licensed to its wholly-owned subsidiary, Biomedical Diagnostics, LLC (Biomedical), has been granted additional patent protection through a Deed of Letters Patent recently issued to the University of Michigan by the Australian Patent Office.

Biomedical is currently developing the Mammastatin technology for use in its Mammastatin Serum Assay (MSA), a breast cancer risk assessment tool.

"We are very pleased with this positive development for Biomedical," said Douglas C. Lane of Experigen Management Company. "Not only does patent grant allow Biomedical to offer its proprietary MSA test in Australia, where one in eleven women of the ten million women population will develop breast cancer during their lifetime, it further validates the global patentability of the Mammastatin technology."

"This is one piece of the domestic and international intellectual property protection strategy we have implemented with the University of Michigan," noted Jim Arthurs, president of Biomedical. "The issuance of this patent is very important as we gain further regulatory approval and market presence for the Mammastatin technology internationally. This newest patent grant expands our worldwide patent protection for MSA."

The MSA was initially developed at the University of Michigan Cancer Center and is licensed exclusively to Biomedical by the university through Genesis Bioventures for scientific and commercial development as a blood test to assess women's health. In scientific correlation studies women who tested high with the MSA assay showed to have lower risk of breast cancer than women who tested low.

More information about Biomedical Diagnostics and the MSA test can